Surgery Partners (SGRY) Stock Price, News & Analysis

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SGRY shares.
View SGRY analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued twelve-month price objectives for Surgery Partners' stock. Their SGRY share price targets range from $35.00 to $50.00. On average, they predict the company's stock price to reach $43.63 in the next year. This suggests a possible upside of 78.3% from the stock's current price.
View analysts price targets for SGRY or view top-rated stocks among Wall Street analysts.

Surgery Partners' stock was trading at $31.99 at the beginning of the year. Since then, SGRY shares have decreased by 23.5% and is now trading at $24.47.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our SGRY earnings forecast.

Surgery Partners, Inc. (NASDAQ:SGRY) announced its earnings results on Monday, February, 26th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.07. The firm had revenue of $735.40 million for the quarter, compared to the consensus estimate of $741.93 million. Surgery Partners had a positive trailing twelve-month return on equity of 3.65% and a negative net margin of 0.43%. The company's quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.22 earnings per share.

ETFs with the largest weight of Surgery Partners (NASDAQ:SGRY) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS) and BlackRock Future Innovators ETF (BFTR).iShares U.S. Healthcare Providers ETF (IHF).

Surgery Partners updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.0 billion-, compared to the consensus revenue estimate of $3.0 billion.

7 employees have rated Surgery Partners Chief Executive Officer Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surgery Partners investors own include Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Glu Mobile (GLUU), Ocular Therapeutix (OCUL), Sangamo Therapeutics (SGMO), Xilinx (XLNX), Allena Pharmaceuticals (ALNA), Editas Medicine (EDIT) and Maxar Technologies (MAXR).

Surgery Partners' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and Cannon Global Investment Management LLC (0.02%). Insiders that own company stock include Andrew T Kaplan, Anthony Taparo, Bradley R Owens, Brent Turner, Danielle Burkhalter, David T Doherty, George Goodwin, Harrison R Bane, Jason Eric Evans, Jennifer Baldock, Laura L Brocklehurst, Laura L Brocklehurst, Marissa Brittenham, Teresa Deluca, Thomas F Cowhey and Wayne S Deveydt.
View institutional ownership trends.

Shares of SGRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.